The effect of antidementia drugs on mortality in patients with Alzheimer’s disease

2019 ◽  
Vol 33 (8) ◽  
pp. 986-993
Author(s):  
Wei-Hao Lin ◽  
Ching-Herng Lin ◽  
Po-Hsun Hou ◽  
Tsuo-Hung Lan

Introduction: Alzheimer’s disease is associated with a higher mortality rate after the diagnosis. We hypothesized that patients with Alzheimer’s disease who received antidementia drugs may have a lower mortality rate than those without such treatment. Methods: Patients with newly diagnosed Alzheimer’s disease aged ⩾65 years during 2001–2006 were identified in the National Health Institute Research Database, Taiwan. We included patients with Alzheimer’s disease who received antidementia drugs as the exposure group (ADD group), and compared them with a non-exposure group who did not receive any antidementia drugs (non-ADD group) matched for age at the index date, gender and Charlson Comorbidity Index score before the index date. All-cause mortality rates and Charlson Comorbidity Index scores at one and two years after the index date were compared between the ADD and non-ADD groups. Results: There were 529 patients in non-ADD group and 529 in the ADD group. The mortality rate was significantly lower in the ADD group compared with the non-ADD group (42% versus 58.6%; p<0.0001). Conclusion: Our results suggest that antidementia drugs may have a protective effect against mortality in patients with Alzheimer’s disease.

2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Chun-Ching Lu ◽  
Hao Qin ◽  
Zi-Hao Zhang ◽  
Cong-Liang Zhang ◽  
Ying-Yi Lu ◽  
...  

Abstract Background Keloids are characterized by disturbance of fibroblast proliferation and apoptosis, deposition of collagen, and upregulation of dermal inflammation cells. This benign dermal fibro-proliferative scarring condition is a recognized skin inflammation disorder. Chronic inflammation is a well-known contributor to bone loss and its sequelae, osteoporosis. They both shared a similar pathogenesis through chronic inflammation. We assessed whether keloids increase osteoporosis risk through using National Health Insurance Research Database. Methods The 42,985 enrolled patients included 8597 patients with keloids but no history of osteoporosis; 34,388 controls without keloids were identified from the general population and matched at a one-to-four ratio by age, gender. Kaplan-Meier method was applied to determine cumulative incidence of osteoporosis. Cox proportional hazard regression analysis was performed after adjustment of covariates to estimate the effect of keloids on osteoporosis risk. Results Of the 8597 patients with keloids, 178 (2.07%) patients were diagnosed with osteoporosis while in the 34,388 controls, 587 (1.71%) were diagnosed with osteoporosis. That is, the keloids patients had 2.64-fold higher risk of osteoporosis compared to controls after adjustment for age, gender, Charlson Comorbidity Index and related comorbidities. The association between keloids and osteoporosis was strongest in patients younger than 50 years (hazard ratio = 7.06%) and in patients without comorbidities (hazard ratio = 4.98%). In the keloids patients, a high incidence of osteoporosis was also associated with advanced age, high Charlson Comorbidity Index score, hyperlipidemia, chronic liver disease, stroke, and depression. Conclusions Osteoporosis risk was higher in patients with keloids compared to controls, especially in young subjects and subjects without comorbidities.


2021 ◽  
Author(s):  
Yu-Lun Ou ◽  
Shu-Heng Huang ◽  
Deng-Chyang Wu ◽  
Hui-Min Hsieh ◽  
Min-Sheng Lee ◽  
...  

Abstract Introduction: Alzheimer’s disease (AD) is the most common form of dementia. Eradication of Helicobacter pylori (H. pylori) could affect the incidence and progression of many diseases; however, there are limited studies of the association between H. pylori eradication and AD outcome. We utilized the National Health Insurance Research Database (NHIRD) of Taiwan to determine the relationship between H. pylori eradication and AD in a diabetes mellitus (DM) population.Methods: We collected data from the NHIRD and the Diabetes Mellitus Health Database in Taiwan of patients without a prior diagnosis of AD. We specified three cohorts: patients with (1) peptic ulcer disease (PUD) but no H. pylori treatment, without DM (PUD-HPRx in GP); (2) PUD and DM, but no H. pylori eradication therapy (PUD-HPRx in DM); (3) PUD and DM, with H. pylori eradication therapy (PUD+HPRx in DM). All cohorts were matched according to age, sex, Charlson Comorbidity Index score, and comorbidities.Results: Data were collected from 2000 to 2010, and 157,231 patients were enrolled in total. We compared the effects of treatment for H. pylori infection on the incidence and mortality of AD. The patients with DM who received H. pylori eradication therapy had a higher incidence of AD than the general population (adjusted hazard ratio of incidence [aHR], 1.088). Subgroup analysis showed that the risk of AD was higher in the younger patients who received H. pylori eradication therapy as compared with those who did not (aHR for younger than 45 years, 1.071; aHR of age 45-54 years, 1.089; aHR of age 55-64 years, 1.079) However, a lower mortality rate was observed in the PUD+HPRx in DM group (aHR, 0.945, compared with PUD-HPRx in DM; P < 0.001).Conclusion: In this study, we demonstrated that DM patients who underwent treatment for eradication of H. pylori had a higher incidence of AD, especially younger patients. Nevertheless, there was a lower mortality rate in patients who received H. pylori treatment. Further study is needed to clarify the interrelated roles of AD and eradication therapy for H. pylori.


2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 856.1-856
Author(s):  
C. Lao ◽  
D. Lees ◽  
D. White ◽  
R. Lawrenson

Background:Osteoarthritis of the hip and knee is one of the most common causes of reduced mobility. It also causes stiffness and pain. Opioids can offer pain relief but is usually used for severe acute pain caused by major trauma or surgery. The use of opioids for relief of chronic pain caused by arthritis has increased over the last few decades.[1]Objectives:This study aims to investigate the use of strong opiates for patients with hip and knee osteoarthritis before and after joint replacement surgery, over a 13 years period in New Zealand.Methods:This study included patients with osteoarthritis who underwent publicly funded primary hip and knee replacement surgeries in 2005-2017 in New Zealand. These records were identified from the National Minimum Dataset (NMD). They were cross referenced with the NZJR data to exclude the admissions not for primary hip or knee replacement surgeries. Patients without a diagnosis of osteoarthritis were excluded.The PHARMS dataset was linked to the NMD to identify the use of strong opiates before and after surgeries. The strong opiates available for community dispensing in New Zealand and included in this study are: dihydrocodeine, fentanyl, methadone, morphine, oxycodone and pethidine. Use of opiate within three months prior to surgery and within 12 months post-surgery were examined by gender, age group, ethnicity, Charlson Comorbidity Index score and year of surgery. Differences by subgroup was examined with Chi- square test. Logistic regression model was used to calculate the adjusted odds ratios of strong opiate use before and after surgery compared with no opiate use.Results:We identified 53,439 primary hip replacements and 50,072 primary knee replacements with a diagnosis of osteoarthritis. Of patients with hip osteoarthritis, 6,251 (11.7%) had strong opiate before hip replacement surgeries and 11,939 (22.3%) had opiate after surgeries. Of patients with knee osteoarthritis, 2,922 (5.8%) had strong opiate before knee replacement surgeries and 15,252 (30.5%) had opiate after surgeries.The probability of patients with hip and knee osteoarthritis having opiate decreased with age, increased with Charlson comorbidity index score, and increased over time both before and after surgeries. Male patients with hip and knee osteoarthritis were less likely to have opiate than female patients both before and after surgeries. New Zealand Europeans with hip and knee osteoarthritis were more likely to receive opiate than other ethnic groups prior to surgeries, but were less likely to have opiate than Asians post-surgeries.Patients who had opiate before surgeries were more likely to have opiate after surgeries than those who did not have opiate before surgeries. The odds ratio was 8.34 (95% confidence interval (CI): 7.87-8.84) for hip osteoarthritis and 11.94 (95% CI: 10.84-13.16) for knee osteoarthritis after adjustment for age, gender, ethnicity, year of surgery and Charlson comorbidity index score. Having opiate prior to surgeries also increased the probability of having opiate for 6 weeks or more after surgeries substantially. The adjusted odds ratio was 21.46 (95% CI: 19.74-23.31) for hip osteoarthritis and 27.22 (95% CI: 24.95-29.68) for knee osteoarthritis.Conclusion:Preoperative opiate holidays should be encouraged. Multiple strategies need to be used to develop analgesic plans that allow adequate rehabilitation, without precipitating a chronic opiate dependence. Clinicians would also benefit from clear guidelines for prescribing strong opiates.References:[1] Nguyen, L.C., D.C. Sing, and K.J. Bozic,Preoperative Reduction of Opioid Use Before Total Joint Arthroplasty.J Arthroplasty, 2016.31(9 Suppl): p. 282-7.Disclosure of Interests:None declared


2019 ◽  
Vol 2019 ◽  
pp. 1-12
Author(s):  
Chih-Ching Liu ◽  
Chung-Yi Li ◽  
Yu Sun ◽  
Susan C. Hu

Background. Very few nationwide studies have focused on the variations in the incidence and prevalence of dementia and Alzheimer’s disease (AD) in Asian countries. This study aims to describe the gender and age differences in the incidence and prevalence of dementia and AD in Taiwan. Methods. The data on dementia and AD were acquired from the Taiwan National Health Insurance Research Database from 2004 to 2010. The sex and age-specific rates were standardized, and the differences of gender and age on dementia or AD were assessed using Poisson regression analysis. Results. Over seven years, the prevalence of dementia and AD significantly increased from 4.7 to 7.6 per hundred people (β = 0.0784, p<0.0001) and 2.3 to 3.5 per hundred people (β = 0.0696, p<0.0001), respectively. However, the incidence of both dementia and AD decreased but not significantly from 10.9 to 10.7 and 4.9 to 4.6 per thousand person-years, respectively. Noticeably, both incidence and prevalence increased with age and were higher in women than in men. Conclusions. The standardized incidence rates of dementia and AD are much lower than the data reported in some studies from Europe, the US, and Japan. Further studies are warranted to explore which factors are associated with the differences in the incidence of dementia and AD in Taiwan.


Drugs & Aging ◽  
2017 ◽  
Vol 34 (4) ◽  
pp. 303-310 ◽  
Author(s):  
Laia Calvó-Perxas ◽  
◽  
Oriol Turró-Garriga ◽  
Joan Vilalta-Franch ◽  
Manuela Lozano-Gallego ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document